Semax

Sequence reference · not a structural model

Semax is identified in the research literature as ACTH(4–7)PGP, a synthetic heptapeptide with the sequence Met–Glu–His–Phe–Pro–Gly–Pro.

The 2020 transcriptome paper describes an ACTH(4–7)-related sequence joined to the C-terminal Pro–Gly–Pro motif. That sequence description is an identity reference; it does not establish a complete molecular mechanism or a specific target interaction.

The sequence graphic below is a text-based research aid—not a resolved molecular structure, assay result, or depiction of binding.

• Seven-residue sequence reported in the cited literature
• ACTH-fragment nomenclature is part of the source identity
• Keep sequence identity separate from mechanism claims

Reported research categories · target remains unresolved

Published work reports changes in neurotrophin-associated measures and gene-expression patterns, while the molecular mechanism remains an open research question.

A rat hippocampus study reported changes in BDNF- and TrkB-related measures after experimental Semax exposure. A separate rat ischemia–reperfusion study examined broader transcript-level changes. These are different experiments, tissues, methods, and questions; they should not be collapsed into one proven pathway.

This map separates reported measurement categories from the unresolved question of how those observations arise. It does not assign a confirmed receptor or causal signaling chain.

• Reported: neurotrophin-associated measures in a rat hippocampus study
• Reported: transcript changes in a separate ischemia–reperfusion model
• Unresolved: a single validated molecular target and full causal mechanism

Study workflow · 2020 paper

The 2020 study used RNA sequencing to examine subcortical brain tissue in a rat transient middle cerebral artery occlusion model.

The paper compared ischemia–reperfusion conditions with and without Semax treatment and analyzed gene-expression patterns at a defined 24-hour time point. The authors reported 394 differentially expressed genes using a greater-than-1.5-fold-change criterion for the Semax-versus-saline comparison under the model conditions.

That count is a study-specific transcriptomic result—not a clinical endpoint and not proof that every listed gene causes a downstream effect. The model, tissue, comparator, analysis threshold, and sampling time are essential context.

• Model: rat transient middle cerebral artery occlusion with reperfusion
• Method: RNA sequencing of subcortical tissue
• Time point: 24 hours; 394 reported differentially expressed genes at the stated threshold

Separate records · different tissue and method

The literature includes distinct research records: a focused hippocampal neurotrophin study and a separate ischemia-related transcriptome study.

The 2006 report examined BDNF- and TrkB-associated measures in rat hippocampus. The 2020 paper examined transcript patterns in subcortical tissue after an ischemia–reperfusion model. The tissue, experimental context, and analytical readouts differ, so their findings are complementary context rather than a direct replication or head-to-head comparison.

A 2023 review provides secondary context for ischemia-related peptide research. Review conclusions should be traced back to the primary experiments and their methods before being treated as direct evidence.

• 2006: hippocampal neurotrophin-related measures
• 2020: subcortical transcriptome under a defined ischemia–reperfusion model
• 2023: secondary review; consult the primary studies for methods and limits

Evidence map · observed measures versus open questions

Bottom line: Semax has a published preclinical research record involving neurotrophin-associated measures and ischemia-related gene-expression analysis, but these records do not settle a complete mechanism.

The transcriptome findings are bounded by the specific rat model, tissue, comparator, assay, and sampling time. Gene-expression differences can identify research leads, but they do not by themselves demonstrate which molecular changes are necessary, sufficient, or causal.

The hippocampal and ischemia-model studies address different research questions. Further interpretation should remain tied to each source's material, methods, measured endpoints, and limitations. The conceptual evidence map below marks what was measured separately from questions that remain open.

• A transcript change is not, by itself, a demonstrated causal mechanism
• Different models and tissues are not interchangeable evidence
• No single confirmed target or complete pathway is asserted here